Cancerforskningsfondet Af 1989

Cancerforskiningsfonden Af 1989

Niels Behrendt

Vincent Ellis

Charles Pyke

Ettore Appella

Michael Ploug

Eeva-Marjatta Salonen

Keld Dano Slashed

Antti Vaheri

Hannele Tapiovaara

Maria Vittoria Cubellis

Ann Louring Roldan

Nils Bruenner

Peter Kristensen

Ebbe Ro Slashednne

Francesco Blasi

Maria Teresa Masucci

Ross W Stephens

Wolf-Dieter Schleuning

Keld Dano

Keld Dan&oslash;

Lisbeth Birk M&oslash;ller

Jari Pollanen

Leif R&oslash;ge Lund

Ebbe R&oslash;nne

L&aacute;szlo Patthy

Wd Schleuning

Gunilla Ho slashedyer-Hansen

Gunilla Hoyer-Hansen

Ebbe Ronne

Jari P&ouml;ll&auml;nen

Laszlo Patthy

Leif Ro Lund

Lisbeth Birk Mo Slashedller

Activation of plasminogen to plasmin is inhibited by preventing the binding of a receptor binding form of urokinase-type plasminogen activator to a urokinase-type plasminogen activator receptor in a mammal, thereby preventing the urokinase-type plasminogen activator from converting plasminogen into plasmin. DNA fragments which encode for soluble, active fragments of the urokinase-type plasminogen activator receptor are provided.

Urokinase-type plasminogen activator receptor

A monoclonal or polyclonal antibody directed against urokinase plasminogen activator receptor (u-PAR), or a subsequence, analogue or glycosylation variant thereof. Antibodies are disclosed which react with free u-PAR or with complexes between u-PA and u-PAR and which are capable of 1) catching u-PAR in ELISA, or 2) detecting u-PAR, e.g. in blotting, or 3) in radioimmunoprecipitation assay precipitate purified u-PAR in intact or fragment form, or 4) is useful for immunohistochemical detection of u-PAR, e.g. in immunostaining of cancer cells, such as in tissue sections at the invasive front, or 5) inhibits the binding of pro-u-PA and active u-PA and thereby inhibits cell surface plasminogen activation. Methods are disclosed 1) for detecting or quantifying u-PAR, 2) for targeting a diagnostic to a cell containing a u-PAR on the surface, 3) for preventing or counteracting proteolytic activity in a mammal. Methods for for selecting a substance suitable for inhibiting u-PA/u-PAR interaction, for preventing or counteracting localized proteolytical activity in a mammal, for inhibiting the invasion and/or metastasis comprise the use of the antibodies and of nude mice inoculated with human cancer cells which are known to invade and/or metastasize in mice and having a distinct color, f.x. obtained by means of an enzyme and a chromogenic substrate for the enzyme, the color being different from the cells of the mouse.

Antibodies and their use

Activation of plasminogen to plasma is inhibited by preventing the binding of a receptor binding form of urokinase-type plasminogen activator to a urokinase-type plasminogen activator receptor in a mammal, thereby preventing the urokinase-type plasminogen activator from converting plasminogen into plasmin. DNA fragments which encode for soluble, active fragments of the urokinase-type plasminogen activator are provided.

Vectors and methods for recombinant production of uPA-binding fragments

Urokinase-type plasminogen activator receptor antibodies

Growing community of inventors

Bagsværd, Denmark

Niels Behrendt